Study Of JAK3 Inhibitor For The Prevention Of Acute Rejection In Kidney Transplant Patients
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
A new immunosuppressive drug based on the inhibition of an important enzyme in the immune
system called JAK3, is being developed by Pfizer to prevent transplant rejection. In this
research study, a JAK3 inhibitor or cyclosporine will be given to new kidney transplant
patients for 12 months in addition to other standard transplant medications such as
prednisone.